Form 4: Regulus Therapeutics Insider Disposes All Holdings Following Novartis Acquisition Completion

Preston Klassen, President and Head of R&D at Regulus Therapeutics Inc., has disposed of all his common stock, performance stock units, and stock options following the completion of the company's acquisition by Novartis AG.

Summary

• Regulus Therapeutics Inc. (RGLS) has been acquired by Novartis AG, with Merger Sub Inc. merging into Regulus, making Regulus a wholly-owned subsidiary of Novartis.
• The acquisition was completed on June 25, 2025, pursuant to an Agreement and Plan of Merger dated April 29, 2025.
• Shareholders received an Offer Price of $7.00 in cash per share (Closing Amount) plus one Contingent Value Right (CVR) per share.
• Each CVR represents the right to receive an additional $7.00 in cash upon the achievement of a specified milestone.
• Preston Klassen, a Director, President & Head of R&D, and former 10% owner, disposed of 115,555 shares of common stock, resulting in zero beneficial ownership.
• His 67,500 performance stock units (PSUs) were canceled and converted into cash (67,500 * $7.00) plus 67,500 CVRs. These PSUs were previously unintentionally omitted from prior Form 4 filings.
• All his in-the-money stock options, totaling 1,898,000 underlying shares across five grants with exercise prices ranging from $1.00 to $2.01, were canceled and converted into cash payments (Closing Amount minus exercise price) plus one CVR per underlying share.

Sentiment

Score: 7

Explanation: The document reports the successful completion of a pre-announced merger, which provides liquidity and potential upside (via CVR) to former shareholders. While the company is no longer independent, the transaction itself is a positive outcome for the reporting person and former shareholders.

Positives

• The completion of the merger provides immediate liquidity to Regulus Therapeutics shareholders and option holders.
• Shareholders receive a fixed cash payment of $7.00 per share, providing certainty.
• The Contingent Value Right (CVR) offers potential for an additional $7.00 per share, providing upside potential tied to a future milestone.
• Preston Klassen, as a key insider, realized significant value from his equity holdings through the merger.

Negatives

• Regulus Therapeutics Inc. ceases to be an independent publicly traded entity, limiting future direct investment opportunities in the company's specific pipeline.
• The value of the Contingent Value Right (CVR) is uncertain and dependent on the achievement of a specific milestone, which may or may not occur.
• The disposition of all securities by a key executive signifies the end of their direct equity interest in the acquired entity.

Risks

• The Contingent Value Right (CVR) payment of $7.00 is contingent upon the achievement of a specified milestone, and there is no guarantee that this milestone will be met, meaning the CVR may expire worthless.

Future Outlook

The future outlook for former Regulus Therapeutics shareholders includes the potential to receive an additional $7.00 per share via a Contingent Value Right (CVR), which is dependent on the achievement of a specific milestone. The company itself is now a wholly-owned subsidiary of Novartis AG.

Industry Context

This acquisition signifies a consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies like Novartis AG acquire smaller biotech firms with promising pipelines (like Regulus Therapeutics, which focuses on microRNA-based therapeutics) to bolster their R&D capabilities and product portfolios. Such mergers are common strategies for growth and innovation in the highly competitive drug development industry.

Comparison to Industry Standards

• The acquisition price of $7.00 cash plus a $7.00 CVR (total potential $14.00) per share for Regulus Therapeutics Inc. by Novartis AG is consistent with industry trends where biotech companies are acquired at premiums reflecting their pipeline potential and strategic value.
• Similar recent acquisitions in the RNA therapeutics space, such as Roche's acquisition of Spark Therapeutics or Gilead's acquisition of Forty Seven, often involve upfront cash payments combined with contingent value rights or earn-outs tied to clinical or regulatory milestones, reflecting the inherent risks and potential rewards in drug development.
• The structure of the deal, including the use of CVRs, is a common mechanism in biotech M&A to bridge valuation gaps and share future risks/rewards between the acquirer and the acquired company's shareholders, particularly for assets in clinical development.

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, providing immediate liquidity and potential future upside. They no longer hold direct equity in an independent Regulus Therapeutics.
• Employees: Regulus Therapeutics employees are now part of Novartis AG, potentially leading to integration and restructuring.
• Management (Preston Klassen): Realized significant value from equity holdings and no longer holds direct beneficial ownership in the acquired entity. His role as President & Head of R&D within the new structure is not detailed but his equity is fully converted.

Next Steps

• Former Regulus Therapeutics shareholders will await the achievement of the specified milestone for the Contingent Value Right (CVR) payment.
• Novartis AG will integrate Regulus Therapeutics' operations and pipeline into its existing structure.

Key Dates

Keywords

Regulus Therapeutics, Novartis AG, Merger, Acquisition, SEC Form 4, Insider Trading, Preston Klassen, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals, Tender Offer, Stock Options, Performance Stock Units